Skip to main content
OpenTrials
Completed

NCT Number: NCT02655081

Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

To provide patients with bladder cancer who are scheduled to undergo radical cystectomy with a preoperative high-arginine nutritional supplement. The investigator will measure patient adherence to the regimen, tolerability of the supplement and feasibility of supplementation. Secondary outcome measures will include differences in length of stay and complication rate between groups.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Shadyside Urology

Pittsburgh, Pennsylvania, 15232, United States

About this study

The purpose of this study is to investigate the use of a high-arginine protein supplement prior to surgery for patients undergoing radical cystectomy for treatment of bladder cancer. As many as 50% of patients who undergo radical cystectomy experience a postoperative complication, and poor preoperative nutritional status is known to increase the risk of complications. Preoperative use of a high-arginine protein shake has been shown to reduce the risk of postoperative complications for patients undergoing surgery for colon cancer, and this study seeks to determine whether this is also true for patients undergoing radical cystectomy for bladder cancer.

Subjects will drink four protein shakes (Nestle Impact AR) per day for 5-7 days prior to radical cystectomy. Shakes will be provided to patients free of charge. On the date of surgery, subjects will turn in a log of shake consumption. Surgery will then proceed in typical fashion, and no changes will be made to surgery or postoperative care. Clinical outcomes for the first 90 postoperative days will be collected. Patient outcomes will be compared to those of contemporary controls who do not undergo supervised nutritional supplementation. Primary study outcome is to assess safety, tolerability and adherence to supplementation regimen. Secondary outcomes include differences in complication rates and length of postoperative hospital stay between groups.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any adult patient seen at one of the aforementioned UPMC facilities who carries a diagnosis of bladder cancer and is considered a candidate for radical cystectomy for treatment.

Exclusion criteria

  • Minors < 18 years of age, patients not considered surgical candidates, patients who do not go on to undergo radical cystectomy. Patients with Glomerular Filtration Rate (GFR) < 30 will also be excluded in an attempt to limit protein intake of patients with Stage IV and V Chronic Kidney Disease. Diabetic patients will be allowed to participate.

Treatment and study plan

high arginine nutritional supplement (Nestle's Impact AR)

Dietary Supplement

Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

Primary outcomes

  1. Safety, tolerability and adherence to supplementation regimen."

    Time frame: 4 months

    Investigator will report on any adverse events from supplementation as well as patient adherence to regimen.

Secondary outcomes

  1. Incidence of 90-day overall and infectious complication rates. I

    Time frame: 4 months

    Investigator will compare overall, infectious and wound complication rates between the study group and control group

  2. Length of hospital stay between study group and control group

    Time frame: 4 months

    The Investigator will compare the length of hospital stay between study group and control group.

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Registry information

Acronym: IMPACT

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jan 13, 2016
Registry last updated
Oct 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.